Adolor Corporation (Nasdaq:ADLR) and GlaxoSmithKline (NYSE:GSK) announced today initial top-line results of the Phase 3 Study 14CL314 of Entereg(R) (alvimopan) for the management of postoperative ileus (POI), by acceleration of the time to recovery of gastrointestinal (GI) function following bowel resection surgery. The Phase 3 study enrolled 654 patients scheduled to undergo large or small bowel resection surgery. The results showed that a 12 mg dose of Entereg(R) achieved a statistically significant difference compared to placebo for the primary endpoint, GI2(*), and for each of the secondary time to event endpoints, including GI3(*) and time to discharge order written.
